Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a ...

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

A recent study reveals the pivotal role of tristetraprolin (TTP), an RNA-binding protein, in regulating inflammatory responses in basophils, immune cells central to allergic reactions. The research ...

Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic ...

Therapeutics announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in ...

Alopecia areata (AA) is a common autoimmune disease that leads to sudden circular hair loss. The clinical course of AA is ...

Asthma, atopic dermatitis or Hashimoto's thyroiditis as concomitant diseases are risk factors for clinical features ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / / CAGE Bio, Inc., a clinical-stage biotechnology company advancing ...